3,120,394 Shares in Boston Scientific Corporation $BSX Purchased by Caisse de depot et placement du Quebec

Caisse de depot et placement du Quebec bought a new position in Boston Scientific Corporation (NYSE:BSX) during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm bought 3,120,394 shares of the medical equipment provider’s stock, valued at approximately $133,178,000. Caisse de depot et placement du Quebec owned about 0.22% of Boston Scientific as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently bought and sold shares of BSX. BlackRock Inc. bought a new stake in shares of Boston Scientific in the 2nd quarter worth approximately $5,534,781,000. State Street Corp boosted its position in Boston Scientific by 1.4% during the 4th quarter. State Street Corp now owns 65,846,059 shares of the medical equipment provider’s stock valued at $6,278,422,000 after purchasing an additional 920,495 shares during the period. Primecap Management Co. CA bought a new position in Boston Scientific during the 2nd quarter worth $2,156,233,000. Capital World Investors increased its position in Boston Scientific by 1.9% in the fourth quarter. Capital World Investors now owns 27,151,575 shares of the medical equipment provider’s stock worth $2,588,953,000 after buying an additional 502,627 shares during the period. Finally, Norges Bank acquired a new stake in Boston Scientific in the fourth quarter worth $2,199,395,000. 89.07% of the stock is currently owned by institutional investors and hedge funds.

Key Stories Impacting Boston Scientific

Here are the key news stories impacting Boston Scientific this week:

• Negative Sentiment: Cyberattack disrupted operations: Boston Scientific said the incident, identified Tuesday, affected information systems used to process customer orders and ship products worldwide. Some systems remain inaccessible, and the company has not provided a firm timeline for full restoration, increasing uncertainty over near-term sales. Reuters report on Boston Scientific cyberattack
• Negative Sentiment: Shipment delays could weigh on results: The disruption is limiting order processing and product deliveries. Investors are concerned that prolonged delays could defer revenue, raise remediation expenses and potentially affect the company’s earnings outlook. CNBC report on Boston Scientific cyberattack
• Negative Sentiment: Additional product-recall concerns: Coverage also highlighted a cardiac-device recall, adding another operational and reputational risk for the medical-device maker at a time when investors are already focused on execution and potential liability. Seeking Alpha report on cardiac device recall
• Neutral Sentiment: Fundamentals provide some support: Boston Scientific recently reported quarterly revenue growth and earnings above analyst expectations, but the cyber incident creates uncertainty about whether that operating momentum can continue in the near term. The Motley Fool coverage of Boston Scientific

Analyst Upgrades and Downgrades

BSX has been the subject of several analyst reports. Piper Sandler reissued an “overweight” rating and set a $65.00 price target on shares of Boston Scientific in a report on Friday, June 12th. Weiss Ratings cut shares of Boston Scientific from a “hold (c-)” rating to a “sell (d+)” rating in a report on Tuesday, July 7th. Oppenheimer cut their price objective on shares of Boston Scientific from $90.00 to $85.00 and set an “outperform” rating on the stock in a research report on Monday, July 27th. Canaccord Genuity Group reduced their target price on shares of Boston Scientific from $70.00 to $66.00 and set a “buy” rating for the company in a research note on Thursday, July 30th. Finally, Leerink Partners set a $60.00 target price on shares of Boston Scientific in a research report on Thursday, July 30th. Twenty-four equities research analysts have rated the stock with a Buy rating, five have assigned a Hold rating and two have assigned a Sell rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $71.62.

Insider Activity

In related news, Director David C. Habiger acquired 2,100 shares of the firm’s stock in a transaction dated Wednesday, August 5th. The stock was acquired at an average cost of $47.59 per share, for a total transaction of $99,939.00. Following the completion of the acquisition, the director directly owned 17,160 shares of the company’s stock, valued at approximately $816,644.40. The trade was a 13.94% increase in their position. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, Director Edward J. Ludwig bought 5,000 shares of the company’s stock in a transaction that occurred on Friday, July 31st. The shares were purchased at an average cost of $45.48 per share, for a total transaction of $227,400.00. Following the acquisition, the director owned 30,359 shares of the company’s stock, valued at $1,380,727.32. This represents a 19.72% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Insiders purchased 194,522 shares of company stock worth $9,385,210 over the last three months. Corporate insiders own 0.34% of the company’s stock.

Boston Scientific Price Performance

Shares of NYSE BSX opened at $48.22 on Thursday. The stock has a market cap of $69.88 billion, a P/E ratio of 19.52, a P/E/G ratio of 1.09 and a beta of 0.56. The firm’s 50-day simple moving average is $46.51 and its 200 day simple moving average is $56.93. Boston Scientific Corporation has a fifty-two week low of $42.20 and a fifty-two week high of $109.50. The company has a quick ratio of 0.74, a current ratio of 1.24 and a debt-to-equity ratio of 0.43.

Boston Scientific (NYSE:BSX) last announced its earnings results on Wednesday, July 29th. The medical equipment provider reported $0.86 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.83 by $0.03. Boston Scientific had a net margin of 17.50% and a return on equity of 19.28%. The firm had revenue of $5.44 billion during the quarter, compared to analyst estimates of $5.38 billion. During the same quarter in the prior year, the firm posted $0.75 EPS. Boston Scientific’s revenue was up 7.5% compared to the same quarter last year. Boston Scientific has set its Q3 2026 guidance at 0.800-0.820 EPS and its FY 2026 guidance at 3.280-3.320 EPS. Equities analysts expect that Boston Scientific Corporation will post 3.3 EPS for the current year.

Boston Scientific declared that its Board of Directors has authorized a stock buyback plan on Monday, May 18th that permits the company to buyback $5.00 billion in shares. This buyback authorization permits the medical equipment provider to reacquire up to 6.4% of its shares through open market purchases. Shares buyback plans are typically a sign that the company’s leadership believes its stock is undervalued.

Boston Scientific Company Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.